School of Medicine
Showing 1-10 of 14 Results
Afrin N. Kamal MD
Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology
Masters Student in Epidemiology and Clinical Research, admitted Autumn 2019
BioAfrin Kamal is a board-certified gastroenterologist, who trained at Washington University in internal medicine, Cleveland Clinic in gastroenterology/hepatology, and most recently Stanford University in esophageal and motility diseases. Afrin shares a clinical passion in esophageal motility diseases with an an overlapping interest in health services and outcomes research.
Ahmad Kamal, MD, MS
Clinical Associate Professor (Affiliated) [Scvmc], Medicine - Med/Gastroenterology and Hepatology
BioDr. Kamal graduated from the University of California at Irvine in 1995 with a B.S. in Biology and received his M.D. from Harvard Medical School in 1999. He completed his residency in Internal Medicine and fellowship in Gastroenterology at Stanford in 2006, during which time he also earned an MSc in Clinical Epidemiology.
In addition to serving as associate chief of the division of gastroenterology at SCVMC, Dr. Kamal is vice chair of internal medicine and director of the clinical research pathway, an innovative program that provides mentoring and protected time for clinical research to internal medicine residents. He is active in teaching trainees at all levels and received an outstanding mentor award from Stanford's biodesign program.
Dr. Kamal has been named a fellow of the American Gastroenterological Association and has been recognized several times in the "Top Doctors" list. He received the Hospital Quality Institute's C. Duane Dauner Award for his work in specialty care transformation and was one of 6 recipients of Silicon Valley Business Journal's Excellence in Healthcare Award. During the COVID-19 pandemic, he served as Director of Health Systems Preparedness for Santa Clara County and was awarded a Medal for Outstanding Service by the Board of Supervisors.
Dr. Kamal has also been active in clinical and health services research, authoring over 20 peer-reviewed publications, 40 abstracts, and 7 book chapters.
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioThe management of inflammatory bowel disease continues to evolve, with the introduction of biologic and small molecule therapies and new goals of treatment, with an emphasis on healing the bowel. My career goal since my graduation from IBD fellowship in 2012 has been to improve the outcomes and quality of life of patients with inflammatory bowel disease. In line with these goals, my research has focused investigating new noninvasive diagnostic test, finding factors early in the disease course that might predict a more aggressive disease course and need for different therapies, and investigating new promising effective medications with less side effects.
Donghee Kim, MD, PhD
Social Sci Res Scholar, Medicine - Med/Gastroenterology and Hepatology
BioI am clinically trained as a physician specialized in gastroenterology and hepatology. My research has focused on clinical research of nonalcoholic fatty liver disease (NAFLD) and obesity-related gastrointestinal diseases, focusing on a population-based study. In addition, my research was not only focused on gastroenterology and was expanded to cardiology, endocrinology, and neurology (sleep medicine). I have experience with large epidemiologic cohort studies as well as clinical trials. This work has resulted in over 200 published papers, including major journals such as Gastroenterology, Hepatology, Gut, Journal of Hepatology, American Journal of Gastroenterology, etc. (as the first and corresponding author). These publications have been cited about 7000 times.
W. Ray Kim
Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center
BioChronic liver disease is one of the most common causes of premature death in Americans. My career goal is to improve the outcome of individuals with chronic liver disease by identifying the optimal means for diagnosis, monitoring, treatment and prevention. The path I have chosen to achieve this goal is through engagement in clinical epidemiology and patient-oriented, effectiveness research.
Since the development of the MELD score which recognizes the importance of renal function in the prognosis of patients with end stage liver disease, one of the areas that we have had intense interest has been acute and chronic renal injury in patients undergoing liver transplantation. Liver transplantation represents a unique opportunity for research, because of the potential for reversal of the renal injury as well as access to biological materials.